25th QSAR

Senior Scientist

Bailey has a background in structural and molecular biology, specialising in the study of kinase complexes during her PhD at Newcastle University and subsequent postdoctoral research at Imperial College London. In 2018, Bailey moved into the life sciences software industry, applying her structural biology and cheminformatics expertise to small molecule discovery. Since then, she has worked with pharmaceutical, agrochemical, and chemical engineering organisations, helping teams integrate machine learning into their discovery workflows.

In her current role at Optibrium™, Bailey works closely with clients to apply Cerella, the company’s deep-learning platform, across hit identification, lead optimisation, and predictive toxicology. She develops and refines machine learning models and delivers training workshops that help clients harness Cerella’s capabilities.

Account Manager

Ewa has over a decade of experience in the life sciences industry with a biotechnology background, supporting clients across the early drug discovery and development journey. She began my career in the CRO sector, helping clients navigate complex processes from hit-to-lead through to GMP API manufacturing, providing tailored solutions to meet their scientific and operational needs. 

In her current role at Optibrium, she combine account management with active promotion of our software solutions. In the account management part of my role, she works closely with clients to build strong, long-term relationships, maintain trust, and expand engagement by understanding their evolving needs and ensuring our solutions continue to deliver value. In the second part of my role, she collaborate with scientific teams across Europe to introduce and promote Optibrium’s software, helping clients optimize drug discovery workflows and accelerate development projects. 

Account Manager 

Jennifer leads Optibrium’s Business Development activities across the UK and Europe, drawing on over 15 years’ experience across healthcare and life sciences. 

She joined the life sciences industry in 2021, bringing extensive experience from the clinical trials sector. At Quanticate and Cytel, she supported clients across Phase I–IV studies, working closely with biopharmaceutical organisations to advance programmes through development.  

With a growing interest in the role of scientific software in accelerating innovation, Jennifer transitioned into drug discovery at Optibrium, where she now partners with organisations to support their research strategies and commercial objectives.